Adverse event (AE) rates by treatment allocation; number of participants in each arm developing at least one AE within each individual organ system
| CTCAE system class | Methylphenidate No of participants with ≥1 event (%) | Placebo No of participants with ≥1 event (%) |
| Ear and labyrinth | 2 (13.3) | 0 |
| Eye | 1 (6.7) | 3 (42.9) |
| Gastrointestinal | 7 (46.7) | 1 (14.3) |
| General disorders | 2 (13.3) | 2 (28.6) |
| Infections and infestations | 1 (6.7) | 1 (14.3) |
| Investigations | 2 (13.3) | 0 |
| Metabolism and nutrition | 1 (6.7) | 0 |
| Musculoskeletal | 5 (33.3) | 1 (14.3) |
| Nervous system | 10 (66.7), 1 SAE (6.7) | 3 (42.9) |
| Psychiatric | 5 (33.3) | 3 (42.9) |
| Respiratory | 7 (46.7) | 6 (85.7) |
| Reproductive system and breast | 1 (6.7) | 0 |
| Skin and subcutaneous tissue | 4 (26.7) | 1 (14.3) |
| Vascular disorders | 2 (13.3) | 0 |
| Any | 14 (93.3) | 7 (100.0) |
CTCAE, Common Terminology Criteria for Adverse Events; SAE, serious AE.